Page 156 - CW E-Magazine (28-1-2025)

News from Abroad

BIOTECH BOOST
Seppic opens lab dedicated to fermentation in US

Seppic, a part of the Air Liquide said the company in a statement. With
group of France, is ramping up its this choice of location, Seppic aims to
investments in biotechnology. benefit from strong synergies with Air
Liquide Group R&D activities on the
The leading maker of speciality ingre- Campus, as well as with the dynamic
dients for cosmetics and pharmaceuticals American research ecosystem in the
recently opened a laboratory dedicated field of biotechnologies.
to fermentation at the group’s Innova- pact on the environment and biodiversity,
tion Campus Delaware, where Seppic’s while minimising impact on land use. “Following the opening in 2024 of
American Customer Technical Service new research facilities at our Castres site
Centre has been based since 2007. “With new equipment and extensive in France, Seppic continues to invest in
know-how, the aim of this laboratory the future with this laboratory in the US.
Fermentation is a process historically will be to develop new ingredients that It will enable us to continue innovating
used to produce and preserve food. Ap- combine efficacy with a response to for the performance of our ingredients
plied to the cosmetics and health markets, societal challenges in the cosmetics and by addressing the needs of our markets,”
this technology enables the production health fields, in line with the company’s said Mr. Hannes Moeller, Chief Execu-
of biobased ingredients with limited im- approach to committed innovation,” tive Officer of Seppic.
Heraeus acquires Umicore’s platinum API business

outside of South America

Heraeus, a German group with demand in the future. Since the 1970s,
diverse business interests, has acquired Heraeus is selling a broad portfolio of
Belgium-based Umicore’s Platinum oncology APIs from Germany to the
active pharmaceutical ingredient (API) world.
business outside of South America.
The business has been transferred to Amongst those are Cisplatin, Carbo-
Heraeus Precious Metals, the precious platin and Oxaliplatin. To ensure availa-
metals division of the Heraeus Group bility of these essential medicines,
and a leading company in the platinum Heraeus will continue to offer Umicore’s
API industry. The increased capacity and the Cisplatin, Carboplatin and Oxaliplatin
acquisition will help the company for a transitional period, alongside the
The acquisition does not include respond promptly to high market corresponding own products.
Umicore’s platinum API business or
production facility in South America Imerys buys Chemviron’s European
and other, non-platinum molecules.
“Our mission is to reliably provide diatomite and perlite business
customers with the highest quality
products – ensuring effective treat- French industrial minerals firm, With this acquisition, Imerys ac-
ment for as many cancer patients as Imerys, has completed the acquisition quires three mining and industrial assets
possible,” said Dr. Andrea Lamberti, of the European diatomite and perlite in France and in Italy, extending and
Head of Pharmaceutical Ingredients business of Chemviron, a subsidiary of complementing its European diatomite
at Heraeus Precious Metals. In 2021, US-based Calgon Carbon Corporation. and perlite footprint. This acquisition
Heraeus Precious Metals had signifi- broadens its filtration and life sciences
cantly expanded its platinum API pro- In 2024, this business generated product portfolio to better serve custo-
duction in Hanau (Germany) with a approximately €50 million in revenue mers in food, beverage, filtration and
multi-million-euro investment. and employed around 130 people. pharmaceutical markets.

156 Chemical Weekly January 28, 2025

Contents Index to Advertisers Index to Products Advertised